TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38015591

Group type: EXPERIMENTAL
Intervention: Inherited thrombophilia cohort
Number of subjects: 241

Group type: COMPARATOR
Intervention: Population-based cohort (PREVHEP-ETHON study)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comparison of cohorts
Number of subjects: 241
Study: 38015598

Group type: EXPERIMENTAL
Intervention: Smartwatch-smartphone dyad for AF detection (Pulsewatch system) plus an electrocardiogram patch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electrocardiogram patch alone
Number of subjects: 120
Study: 38015602

Group type: EXPERIMENTAL
Intervention: Model 4 (using frequent responder indicator)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Model using events data and VFRs' previous experience (without demographic data)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Model using events data only
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: J48 decision tree algorithm
Number of subjects: 112
Study: 38015658

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control
Number of subjects: 750
Study: 38015745

Group type: EXPERIMENTAL
Intervention: ESC high-risk patients (n=717, 75.3%)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: CSRS categories
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Overall management of syncope in ED
Number of subjects: 952
Study: 38015833

Group type: EXPERIMENTAL
Intervention: POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: POC-PCR
Number of subjects: 294

Group type: COMPARATOR
Intervention: SCO (standard care only)
Number of subjects: 294
Study: 38015877

Group type: COMPARATOR
Intervention: Nonoperative treatment (control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Locking plate (LP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 160
Study: 38015901

Group type: EXPERIMENTAL
Intervention: Peer-based club intervention
Number of subjects: 222
Study: 38016021

Group type: EXPERIMENTAL
Intervention: BNT162b2-Omi.BA.4/BA.5 (30-µg second booster)
Number of subjects: 727
Study: 38016085

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 38016127

Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis (TASC A/B)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis (TASC C/D)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis
Number of subjects: 655
Study: 38016160

Group type: EXPERIMENTAL
Intervention: TB-ART treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: ART-only group
Number of subjects: 152
Study: 38016322

Group type: EXPERIMENTAL
Intervention: Adjuvanted protein vaccine (5, 15 or 45 μg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: mRNA vaccine (10, 20, or 50 μg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 76
Study: 38016431

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (median logMAR 0.18, IQR 0.06-0.26)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity (LLVA) (median logMAR 0.66, IQR 0.36-0.88)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microperimetry mean sensitivity (18.4 dB, IQR 9.21-20.9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Development of macular neovascularizations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between square root GA area and visual function tests
Number of subjects: 30
Study: 38016468

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular transplantation of allogeneic human neural stem/progenitor cells (hNSCs)
Number of subjects: 15
Study: 38016482

Group type: EXPERIMENTAL
Intervention: Pucotenlimab at 200 mg every 3 weeks
Number of subjects: 100
Study: 38016718

Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (arm A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (arm B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 63
Study: 38016950

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1500 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 38016958

Group type: EXPERIMENTAL
Intervention: PrEP users (n=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-PrEP users (n=24)
Number of subjects: 48
Study: 38017103

Group type: EXPERIMENTAL
Intervention: Women with normal karyotype, FLT3-ITD, DNMT3A, NPM1, and WT1 mutations
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Men with complex karyotype, ASXL1, SRSF2, U2AF1, RUNX1, or KIT mutations
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Women in the 2022 European LeukemiaNet intermediate-risk group
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Men in adverse-risk group
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: SF3B1 mutations in patients aged <60 years
Number of subjects: 1726
Study: 38017197

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Stepwise increase and decrease in Positive End Expiratory Pressure (STEP)
Number of subjects: 35
Study: 38017325

Group type: EXPERIMENTAL
Intervention: EMI-137 (0.09 mg/kg, 0.13 mg/kg, 0.18 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EMI-137 (0.13 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EMI-137-guided MFGI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EMI-137
Number of subjects: 14
Study: 38017340

Group type: EXPERIMENTAL
Intervention: IGV-001 (autologous cell product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 38017388

Group type: EXPERIMENTAL
Intervention: Geriatric hotlines
Number of subjects: 4137
Study: 38017432

Group type: EXPERIMENTAL
Intervention: High levels of IL-6 (≥9.5 pg/mL)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (210 controls)
Number of subjects: 310
Study: 38017467

Group type: EXPERIMENTAL
Intervention: Physical activity health coaching intervention
Number of subjects: 290

Group type: COMPARATOR
Intervention: General healthy aging education program
Number of subjects: 290
Study: 38017482

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Dapagliflozin-saxagliptin
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 38017500

Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen (10 g) and vitamin C (40 mg) supplementation for 24 weeks combined with progressive tendon loading exercises (PTLE)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (10 g maltodextrin) combined with progressive tendon loading exercises (PTLE)
Number of subjects: 76
Study: 38017522

Group type: EXPERIMENTAL
Intervention: Measurement-Based Care (MBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic implementation methods (including rapid evidence synthesis, rapid ethnography, design kits, barrier prioritization, causal pathway diagramming)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toolkit for design kit methods co-designed with youth and communities
Number of subjects: 0
Study: 38017564

Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 24
Study: 38017574

Group type: EXPERIMENTAL
Intervention: ReSeT intervention (online psychoeducational program and video therapy sessions)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ReSeT intervention
Number of subjects: 106
Study: 38017663

Group type: EXPERIMENTAL
Intervention: Perampanel as add-on therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perampanel as substitution therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perampanel (overall)
Number of subjects: 100
Study: 38018158

Group type: EXPERIMENTAL
Intervention: Daily egg consumption for six months
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study: 38018175

Group type: EXPERIMENTAL
Intervention: HdxSim
Number of subjects: 0

Group type: COMPARATOR
Intervention: MWPharm-DOS
Number of subjects: 0
Study: 38018460

Group type: EXPERIMENTAL
Intervention: Tislelizumab (anti-PD-1 antibody) added to radiation therapy
Number of subjects: 0
Study: 38018707

Group type: EXPERIMENTAL
Intervention: Impedance-dependent tissue sealer (IDTS) tonsillectomy
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Cold steel tonsillectomy
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1250
Study: 38018702

Group type: EXPERIMENTAL
Intervention: Statins (equivalent to 20 mg/day of simvastatin)
Number of subjects: 50725

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 50725
Study: 38018833

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point ≥10)
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Baseline Glasgow Coma Scale score
Number of subjects: 2829

Group type: COMPARATOR
Intervention: ICH score
Number of subjects: 2829

Group type: COMPARATOR
Intervention: max-ICH score
Number of subjects: 2829

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point 10)
Number of subjects: 2829

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point 12)
Number of subjects: 2829
Study: 38018840

Group type: EXPERIMENTAL
Intervention: IVUS-guided treatment decision
Number of subjects: 1682

Group type: COMPARATOR
Intervention: FFR-guided treatment decision
Number of subjects: 1682
Study: 38018841

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 192

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 192
Study: 38019014

Group type: EXPERIMENTAL
Intervention: Germline RUNX1 variants
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Somatic mutations in CHIP or AML driver genes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Monitoring changes in somatic mutations
Number of subjects: 51
Study: 38019088

Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA, RBL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38019116

Group type: EXPERIMENTAL
Intervention: Giredestrant 30 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Giredestrant 90 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Giredestrant 100 mg combined with palbociclib 125 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Giredestrant 10, 30, 90, or 250 mg once daily (dose-escalation stage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Giredestrant 30, 100, and 250 mg once daily (dose-expansion stage)
Number of subjects: 0
Study: 38019287

Group type: EXPERIMENTAL
Intervention: Healthy sensory profile (HSP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Thermal hyperalgesia (TH)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mechanical hyperalgesia (MH)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sensory loss (SL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Comparison of phenotypes
Number of subjects: 76
Study: 38019355

Group type: EXPERIMENTAL
Intervention: BI 1358894 (oral, single ascending dose, 3-50 mg in fasted state; 50-200 mg in fed state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1358894 (oral, multiple ascending doses, 10-200 mg)
Number of subjects: 0
Study: 38019356

Group type: EXPERIMENTAL
Intervention: BI 1358894 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 38019444

Group type: EXPERIMENTAL
Intervention: Metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Metronomic oral cyclophosphamide and methotrexate (CM) alone (Arm B)
Number of subjects: 55
Study: 38019467

Group type: EXPERIMENTAL
Intervention: Parent-led, telehealth-delivered cognitive behavioral therapy (CBT) program
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 38019512

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided revascularization
Number of subjects: 1639
Study: 38019571

Group type: EXPERIMENTAL
Intervention: Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Coaching condition (2 telephone coaching sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No-coaching condition (no subsequent coaching)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: STEP-YA intervention
Number of subjects: 74
Study: 38019593

Group type: EXPERIMENTAL
Intervention: Acceptance and Mindfulness-Based Exposure Therapy
Number of subjects: 0
Study: 38019656

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccines (third doses)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 78
Study: 38019657

Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 220 mg iso-osmolar product A
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 660 mg iso-osmolar product B
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 660 mg hypo-osmolar product C
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All three tenofovir douches
Number of subjects: 21
Study: 38019901

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg with concomitant immunomodulator (IM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study: 38019956

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) injection of 2 × 106 to 16 × 106 colony-forming units
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) injection
Number of subjects: 92
Study: 38019968

Group type: EXPERIMENTAL
Intervention: Conservative airway strategy of intubation withholding
Number of subjects: 225

Group type: COMPARATOR
Intervention: Routine practice (intubation)
Number of subjects: 225
Study: 38020057

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 39357

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 39357

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 39357
Study: 38020116

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Opioid-sparing anesthesia (OSA)
Number of subjects: 124
Study: 38020175

Group type: EXPERIMENTAL
Intervention: GA + EA (General Anesthesia + Epidural Anesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GA alone (General Anesthesia only)
Number of subjects: 60
Study: 38020201

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy subjects (metabolic controls)
Number of subjects: 16
Study: 38020288

Group type: EXPERIMENTAL
Intervention: Berotralstat (150 mg daily)
Number of subjects: 39
Study: 38020522

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment for overactive bladder
Number of subjects: 1504
Study: 38020587

Group type: EXPERIMENTAL
Intervention: Body Scan
Number of subjects: 147
Study: 38020626

Group type: EXPERIMENTAL
Intervention: ICF-based post-stroke rehabilitation program (ICF-PSRP)
Number of subjects: 52
Study: 38021090

Group type: EXPERIMENTAL
Intervention: SBRT with optical skin surface motion monitoring and breath-hold technique
Number of subjects: 10
Study: 38021251

Group type: EXPERIMENTAL
Intervention: Rumination-focused cognitive behavioral therapy (RF-CBT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 76
Study: 38021297

Group type: EXPERIMENTAL
Intervention: Amnion collagen matrix wrap and bone marrow aspirate concentrate (BMAC) injection during graft preparation.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard ACLR (control group).
Number of subjects: 40
Study: 38021373

Group type: EXPERIMENTAL
Intervention: Consecutive-day group (daily 100 mg iron for 90 d, followed by daily placebo for another 90 d)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Alternate-day group (same daily dose of iron and placebo on alternate days for 180 d)
Number of subjects: 150
Study: 38022532

Group type: EXPERIMENTAL
Intervention: E7777 + anti-PD-1
Number of subjects: 100

Group type: COMPARATOR
Intervention: E7777
Number of subjects: 100

Group type: COMPARATOR
Intervention: anti-PD-1
Number of subjects: 100
Study: 38022553

Group type: EXPERIMENTAL
Intervention: XELOX combined with anlotinib and penpulimab for 6-8 cycles, maintained with anlotinib and penpulimab for up to 1 year
Number of subjects: 300

Group type: COMPARATOR
Intervention: XELOX alone for 6-8 cycles
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ctDNA positive patients
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ctDNA negative patients
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 300
Study: 38022664

Group type: EXPERIMENTAL
Intervention: CIK-SOX (autologous CIK cells combined with S-1+oxaliplatin)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SOX (S-1+oxaliplatin)
Number of subjects: 59
Study: 38022757

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (females without MS)
Number of subjects: 30
Study: 38022953

Group type: EXPERIMENTAL
Intervention: MCT-Silver
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 0
Study: 38023148

Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib + Thalidomide + Dexamethasone (VTD)
Number of subjects: 0
Study: 38023544

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (2 doses at months 0 and 1)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Standard of care (receipt of COVID-19 vaccine)
Number of subjects: 1149
Study: 38023545

Group type: EXPERIMENTAL
Intervention: Better WASH households (defined by safe source of water for daily use, safe source of drinking water, private/shared flush toilet use, and always handwashing with soap after defecation)
Number of subjects: 55086

Group type: COMPARATOR
Intervention: Control population (not specified in detail)
Number of subjects: 55086
Study: 38023553

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG; 50 mg once per day) plus Darunavir boosted with cobicistat (DRV/c; 800/150 mg once per day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) regimen
Number of subjects: 89
Study: 38023556

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral treatments for HCV
Number of subjects: 498
Study: 38023564

Group type: EXPERIMENTAL
Intervention: Third SARS-CoV-2 vaccine (mRNA-1273 or BNT162b2)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: BNT162b2 (Pfizer-BioNTech)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Third vaccination in solid organ transplant recipients
Number of subjects: 580

Group type: COMPARATOR
Intervention: Basic immunization (first and second vaccines)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: People living with HIV
Number of subjects: 580
Study: 38023964

Group type: EXPERIMENTAL
Intervention: prevANS intervention (self-guided, online, via web or smartphone app)
Number of subjects: 2000
Study: 38023967

Group type: EXPERIMENTAL
Intervention: iRTP (internet-based recovery training program)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 69
Study: 38024244

Group type: EXPERIMENTAL
Intervention: Cediranib (20 mg) in combination with radiation and temozolomide
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo in combination with radiation and temozolomide
Number of subjects: 137
Study: 38024477

Group type: EXPERIMENTAL
Intervention: BendaEAM
Number of subjects: 108
Study: 38025217

Group type: EXPERIMENTAL
Intervention: Drug-induced acute kidney injury (DI-AKI) cases
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Nephrotoxic drugs (e.g., vancomycin, NSAIDs, piperacillin/tazobactam)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Clinical characteristics and predictive variables of DI-AKI
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Model performance
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability (IRR) for DI-AKI adjudication
Number of subjects: 314
Study: 38025406

Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transportation service for enrolled participants
Number of subjects: 100
Study: 38025416

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-world polypharmacy treatment strategies
Number of subjects: 0
Study: 38025433

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine treatment (RWT)
Number of subjects: 0
Study: 38025437

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation (cTBS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham theta-burst stimulation
Number of subjects: 28
Study: 38025483

Group type: EXPERIMENTAL
Intervention: e-Motional Training® (ET)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ET)
Number of subjects: 50
Study: 38025545

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measurements at the site above the central part of the placenta
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control measurements outside of the placenta on the lower abdomen
Number of subjects: 34
Study: 38025650

Group type: EXPERIMENTAL
Intervention: AF induction by burst pacing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no AF induction)
Number of subjects: 42